Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 6,440 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Kidney Clear all
Completed Phase 3 Interventional

Survival Study Of Oncophage® vs. Observation In Patients With Kidney Cancer

NCT00033904
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
autologous human tumor-derived HSPPC-96
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
650 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2007
U.S. locations
39
States / cities
Anchorage, Alaska • Tucson, Arizona • Los Angeles, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2012 · Synced Oct 31, 2026, 2:48 AM EDT
Terminated Phase 3 Interventional

WP16302 A Bioequivalence Study Comparing Ganciclovir From the Valganciclovir Syrup Formulation and the Commercial Valganciclovir 450mg Tablet (Valcyte®) at a Dose of 900mg in Kidney Transplant Recipients

NCT00275314
View directory record Official record
Conditions
Kidney Transplant
Interventions
Valganciclovir
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 68 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 17, 2015 · Synced Oct 31, 2026, 2:48 AM EDT
Completed No phase listed Observational

Noninvasive Measurements of Renal Perfusion During Cardiac Surgery

NCT03335865
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 31, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

DapagliFLOzin in Renal AL Amyloidosis (FLORAL)

NCT06420167
View directory record Official record
Conditions
Renal AL Amyloidosis
Interventions
Dapagliflozin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Blood Pressure Lowering in Dialysis (BOLD) Trial

NCT03459807
View directory record Official record
Conditions
Blood Pressure, End Stage Renal Disease on Dialysis (Diagnosis), Chronic Kidney Diseases, Chronic Kidney Disease Stage 5
Interventions
Anti-Hypertensive medications, Dry Weight Adjustment
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 100 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
San Francisco, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Early Phase 1 Interventional

Effects of Vitamin D Replacement on Hormones Regulating Iron Metabolism in Individuals With Chronic Kidney Disease

NCT01988116
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia of Chronic Disease
Interventions
Oral Calcitriol 0.5 mcg once daily for 6 weeks, Placebo
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 24, 2015 · Synced Oct 31, 2026, 2:48 AM EDT
Completed No phase listed Observational

Clinical and Histopathologic Characteristics of BAP1 Mutations

NCT01773655
View directory record Official record
Conditions
Malignant Pleural Mesothelioma (MPM), Choroidal Nevus, Primary Uveal Melanoma (UM), Metastatic Uveal Melanoma (UM), Renal Cell Carcinoma, Cholangiocarcinoma
Interventions
tumor specimens
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
196 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
2
States / cities
Harrison, New York • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 31, 2026, 2:48 AM EDT
Withdrawn Not applicable Interventional

Transversus Abdominis Plane (TAP) Block After Kidney Transplantation

NCT01496729
View directory record Official record
Conditions
Transplantation, Kidney
Interventions
Transversus abdominis plane (TAP) block, Sham TAP block with normal saline
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2013 · Synced Oct 31, 2026, 2:48 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prognostic Indicators as Provided by the EPIC ClearView

NCT01476995
View directory record Official record
Conditions
Coronary Artery Disease, Congestive Heart Failure, Valvular Heart Disease, Atrial Fibrillation, Hypertension, Pyelonephritis, Acute Renal Failure, Renal Failure, Viral Hepatitis, Alcoholic Hepatitis, Steatohepatitis, Cirrhosis, Asthma, COPD, Bronchitis, Emphysema, Pneumonia, Inflammatory Bowel Disease, Crohn's Disease, Ulcerative Colitis, Diverticulitis, Peptic Ulcer Disease, Irritable Bowel Syndrome, Cholecystitis, Pancreatitis, Malabsorption Disorders, Celiac Sprue, Diabetes
Interventions
Not listed
Lead sponsor
Epic Research & Diagnostics, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
353 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 22, 2011 · Synced Oct 31, 2026, 2:48 AM EDT
Recruiting Phase 1 Interventional

A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077)

NCT07199465
View directory record Official record
Conditions
Cytomegalovirus Prophylaxis
Interventions
Letermovir
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
Up to 17 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 4 Interventional

The Role of Vitamin D in Immune Function in Patients With Chronic Kidney Disease (CKD) Stages 3 and 4.

NCT00749736
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
cholecalciferol, doxercalciferol, placebo
Dietary Supplement
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 29, 2013 · Synced Oct 31, 2026, 2:48 AM EDT
Withdrawn Phase 2 Interventional

Study of the Safety and Effectiveness of Rilonacept (IL-1 Trap) Administered Subcutaneously in Subjects With Non Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) and Anemia

NCT00609544
View directory record Official record
Conditions
Chronic Kidney Disease, Anemia
Interventions
Rilonacept
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
27
States / cities
Alexander City, Alabama • Muscle Shoals, Alabama • Cerritos, California + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of RBT-1 in Healthy Volunteers and Subjects With Stage 3/4 Chronic Kidney Disease

NCT03893799
View directory record Official record
Conditions
Healthy Volunteers, Chronic Kidney Disease
Interventions
RBT-1
Drug
Lead sponsor
Renibus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Edgewater, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function

NCT07342881
View directory record Official record
Conditions
Chronic Hepatitis B Infection
Interventions
Pevifoscorvir Sodium (ALG-000184)
Drug
Lead sponsor
Aligos Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
2
States / cities
Orlando, Florida • Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Not applicable Interventional Results available

Study to Determine the Efficacy of Real-time CGM in Preventing Hypoglycemia Among Insulin-treated Patients With DM2 on Hemodialysis, Compared to Standard of Care (POC BG)

NCT04473430
View directory record Official record
Conditions
End-Stage Renal Disease, Type 2 Diabetes
Interventions
Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
Device
Lead sponsor
Emory University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 31, 2026, 2:48 AM EDT
Terminated Phase 2 Interventional Results available

Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma

NCT00557830
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Sorafenib Escalated Dose, Sorafenib Standard Dose
Drug
Lead sponsor
Accelerated Community Oncology Research Network
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
13
States / cities
Jonesboro, Arkansas • La Verne, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2013 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

NCT02966028
View directory record Official record
Conditions
Cardiovascular Diseases, Cardiovascular Abnormalities, Calcifications, Vascular, Endstage Renal Disease, ESRD, Coronary Artery Calcification
Interventions
SNF472, Placebo
Drug
Lead sponsor
Sanifit Therapeutics S. A.
Other
Eligibility
18 Years to 80 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
46
States / cities
Bakersfield, California • Chula Vista, California • Escondido, California + 42 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2021 · Synced Oct 31, 2026, 2:48 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Impact of CAMP in an Ambulatory Renal Clinic

NCT00599365
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Pharmacy care arm
Other
Lead sponsor
San Francisco Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 15, 2008 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Results available

HEPLISAV-B® in Adults With End-Stage Renal Disease (ESRD) Undergoing Hemodialysis

NCT03934736
View directory record Official record
Conditions
End Stage Renal Disease on Hemodialysis (Diagnosis)
Interventions
HEPLISAV-B®
Drug
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
20
States / cities
Bloomfield, Connecticut • Middlebury, Connecticut • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 31, 2026, 2:48 AM EDT
Completed No phase listed Observational

Survey of Adherence to Immunosuppression and Other Medications in Kidney Transplant Patients

NCT00433134
View directory record Official record
Conditions
Kidney Transplantation, Treatment Refusal, Patient Compliance
Interventions
Adherence
Behavioral
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 24, 2009 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Effect of Renal Impairment on the Pharmacokinetics of Isavuconazole.

NCT01555866
View directory record Official record
Conditions
Pharmacokinetics of Isavuconazole, Healthy Volunteers, Renal Impaired
Interventions
isavuconazole
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Denver, Colorado • Miami, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Oct 31, 2026, 2:48 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies

NCT03829501
View directory record Official record
Conditions
Squamous Cell Carcinoma of Head and Neck, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Esophageal Cancer, Gastric Cancer, Melanoma, Renal Cell Carcinoma, Pancreatic Cancer, Cervical Cancer, Triple Negative Breast Cancer, Advanced Cancer, Metastatic Cancer
Interventions
Alomfilimab, Atezolizumab
Drug
Lead sponsor
Kymab Limited
Industry
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
6
States / cities
Duarte, California • New Haven, Connecticut • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2025 · Synced Oct 31, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency

NCT01958281
View directory record Official record
Conditions
HCV Infection
Interventions
SOF, RBV, LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
7
States / cities
San Francisco, California • Miami, Florida • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 8, 2018 · Synced Oct 31, 2026, 2:48 AM EDT
Active, not recruiting No phase listed Observational

Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma

NCT03291028
View directory record Official record
Conditions
Renal Cell Carcinoma, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer, Urethral Cancer
Interventions
Immune checkpoint inhibitor targeting PD1
Biological
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 31, 2026, 2:48 AM EDT